- Home
- FCO vs EVAX Comparison
FCO vs EVAX Comparison
Compare FCO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCO | EVAX |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 33.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FCO | EVAX |
|---|---|---|
| Price | $3.10 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | ★ 100.1K | 73.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 14.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $4.73 | $1.20 |
| 52 Week High | $6.63 | $12.15 |
Technical Indicators
Market Signals| Indicator | FCO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 27.10 |
| Support Level | $3.11 | $3.10 |
| Resistance Level | $3.26 | $3.35 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 50.91 | 10.91 |
Price Performance
Historical ComparisonAbout FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.